Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Maxamine enters phase III for malignant melanoma

July 15, 1997

Jenner Technologies reports results from phase I/II trial of prostate cancer vaccine

July 9, 1997

MDX-210 shows promise in advanced kidney and prostate cancer

July 1, 1997

Ajinomoto prepares peptides for treating or preventing human gastric cancer

June 30, 1997

Novopharm Biotech issued U.S. patent for two human monoclonal antibodies

June 27, 1997

Lidak reports promising phase I/II data with melanoma vaccine

June 27, 1997

Phase I studies reported for P&U fusion protein for GI malignancies

June 23, 1997

FDA advisory committee to review rituximab BLA

June 20, 1997

Novopharm Biotech files Canadian IND for hMAb

June 12, 1997

Cel-Sci receives approval to begin Multikine trial in Canada

June 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...